• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Valeant buys Johnson & Johnson skincare unit for $345 million

Valeant buys Johnson & Johnson skincare unit for $345 million

July 19, 2011
CenterWatch Staff

Valeant Pharmaceuticals wants to become the world's biggest player in the skincare sector in about five years, its top executive told Reuters. The company has been signaling its intent with a string of recent mid-sized acquisitions in the highly fragmented but lucrative dermatology sector.

The specialty drug maker will pay $345 million to buy the skincare unit of Johnson & Johnson-owned Janssen Pharmaceuticals.

Valeant plans to continue making deals in dermatology as it looks to reach the top faster, chief executive Michael Pearson said. Once its recent deals close, the company will record about $1 billion in revenue from dermatology.

While there is significant competition in the dermatology arena, Valeant will be facing smaller rivals rather than the pharmaceutical giants, which have been beating a hasty retreat from the sector as they look to narrow their focus.

Pearson's philosophy has been to stay clear of the so-called Big Pharma companies but engage in partnerships with them instead. The company is still considering larger takeovers and can pull off a $6 billion deal, Pearson said.

"They're out there buying assets for cash flow and building a broad dermatology presence. It seems like a pretty sound strategy to me," Stifel Nicolaus analyst Annabel Samimy said. "The assets that they're buying are not necessarily the ones that require a significant amount of promotion or expense behind them."

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing